PMID- 35623086
OWN - NLM
STAT- MEDLINE
DCOM- 20220617
LR  - 20230929
IS  - 1473-558X (Electronic)
IS  - 0959-4965 (Print)
IS  - 0959-4965 (Linking)
VI  - 33
IP  - 10
DP  - 2022 Jul 6
TI  - Effects of ginsenoside Rg1 on proliferation and directed differentiation of human 
      umbilical cord mesenchymal stem cells into neural stem cells.
PG  - 413-421
LID - 10.1097/WNR.0000000000001795 [doi]
AB  - OBJECTIVE: Human umbilical cord mesenchymal stem cells (hUCMSCs) can be 
      transformed into neural stem cells (NSCs) and still maintain immunomodulatory and 
      antioxidant effects. Transplantation of NSCs induced by hUCMSCs would be a 
      promising therapeutic strategy for the treatment of neurological diseases. 
      Ginsenoside Rg1 has neuroprotective effects and influences cell proliferation and 
      differentiation. In this study, we further evaluated the effects of ginsenoside 
      Rg1 on the proliferation and directional differentiation of hUCMSCs into NSCs. 
      METHODS: The CCK-8 assay was used to determine the optimal dose of ginsenoside 
      Rg1 with respect to hUCMSC proliferation and differentiation. NSCs were 
      authenticated using immunofluorescence staining and flow cytometry and were 
      quantified in each group. RT-PCR was used to screen the signaling pathway by 
      which ginsenoside Rg1 promoted the differentiation of hUCMSCs into NSCs. RESULTS: 
      The optimal dose of Rg1 to promote hUCMSC proliferation and differentiation to 
      NSCs was 10 mumol/l. Flow cytometry and immunofluorescence showed that induced 
      NSCs expressed nestin and sex-determining region Y-box 2, with higher expression 
      levels in the Rg1 group than that in the negative control group. RT-PCR showed 
      that Rg1 downregulates the expression of genes involved in Wnt/beta-catenin and 
      Notch signaling pathways in the induction process. CONCLUSION: Ginsenoside Rg1 
      not only promotes the proliferation and viability of hUCMSCs in the process of 
      differentiation into NSCs but also improves the differentiation efficiency. This 
      study provides a basis for the development of hUCMSC-derived NSCs for the 
      treatment of nervous system diseases and for analyses of underlying biological 
      mechanisms.
CI  - Copyright (c) 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Xiao, Li
AU  - Xiao L
AD  - Department of Rehabilitation, The First Affiliated Hospital of Gannan Medical 
      University.
AD  - Ganzhou Key Laboratory of Rehabilitation Medicine.
FAU - Wang, Maoyuan
AU  - Wang M
AD  - Department of Rehabilitation, The First Affiliated Hospital of Gannan Medical 
      University.
AD  - Ganzhou Key Laboratory of Rehabilitation Medicine.
FAU - Zou, Kang
AU  - Zou K
AD  - Intensive Care Unit, The First Affiliated Hospital of Gannan Medical University.
FAU - Li, Zuoyong
AU  - Li Z
AD  - Department of Pharmacy, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou.
FAU - Luo, Jun
AU  - Luo J
AD  - Department of Rehabilitation, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220530
PL  - England
TA  - Neuroreport
JT  - Neuroreport
JID - 9100935
RN  - 0 (Ginsenosides)
RN  - PJ788634QY (ginsenoside Rg1)
SB  - IM
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - *Ginsenosides/pharmacology
MH  - Humans
MH  - *Mesenchymal Stem Cells
MH  - *Neural Stem Cells/metabolism
MH  - Umbilical Cord
PMC - PMC9154301
COIS- There are no conflicts of interest.
EDAT- 2022/05/28 06:00
MHDA- 2022/06/18 06:00
PMCR- 2022/05/31
CRDT- 2022/05/27 17:21
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/06/18 06:00 [medline]
PHST- 2022/05/27 17:21 [entrez]
PHST- 2022/05/31 00:00 [pmc-release]
AID - 00001756-202207010-00004 [pii]
AID - 10.1097/WNR.0000000000001795 [doi]
PST - ppublish
SO  - Neuroreport. 2022 Jul 6;33(10):413-421. doi: 10.1097/WNR.0000000000001795. Epub 
      2022 May 30.